Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2006

Angel to Manufacture Materials for CellCure Phase II Trials

  • Angel Biotechnology Holdings signed a development and GMP manufacturing deal with CellCure. Angel will manufacture and supply GMP materials for use in a T-cell based immuno-therapy as part of a Phase II trial to evaluate the treatment in patients with metastatic malignant melanoma.

    "Having worked only with laboratory-grown T cells in the past, the development of a final and fully GMP compliant bio-pharmaceutical preparation is crucial to our future success,” points out Anders Trojel, CEO of CellCure.

    The GMP production scale-up project, to be conducted at Angel's facilities, will last for 18 months.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »